Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020063433 - ANTI-TUMOR USE OF ANTI-PROGRAMMED DEATH LIGAND-1 (PD-L1) ANTIBODY

Publication Number WO/2020/063433
Publication Date 02.04.2020
International Application No. PCT/CN2019/106599
International Filing Date 19.09.2019
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • 四川科伦博泰生物医药股份有限公司 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 刘平 LIU, Ping
  • 王军 WANG, Jun
  • 肖亮 XIAO, Liang
  • 薛彤彤 XUE, Tongtong
  • 罗毅 LUO, Yi
  • 王利春 WANG, Lichun
  • 王晶翼 WANG, Jingyi
Agents
  • 中国国际贸易促进委员会专利商标事务所 CCPIT PATENT AND TRADEMARK LAW OFFICE
Priority Data
201811144919.229.09.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) ANTI-TUMOR USE OF ANTI-PROGRAMMED DEATH LIGAND-1 (PD-L1) ANTIBODY
(FR) UTILISATION ANTI-TUMORALE D'UN ANTICORPS ANTI-LIGAND DE MORT PROGRAMMÉE 1 (PD-L1)
(ZH) 抗程序性死亡配体-1(PD-L1)抗体的抗肿瘤用途
Abstract
(EN)
The present invention provides a use of an anti-programmed death ligand-1 (PD-L1) antibody in preparation of medications for treating tumors, such as lymphomas or solid tumors.
(FR)
La présente invention concerne une utilisation d'un anticorps anti-ligand de mort programmée 1 (PD-L1) dans la préparation de médicaments pour le traitement de tumeurs, telles que des lymphomes ou des tumeurs solides.
(ZH)
本发明提供了抗程序性死亡配体-1(PD-L1)抗体用于制备治疗肿瘤(例如淋巴瘤或实体瘤)药物的用途。
Latest bibliographic data on file with the International Bureau